Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

# Summary of HR 1796: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 This bill would establish federal funding and programs focused on sickle cell disease and other inherited blood disorders. The legislation would likely direct resources toward medical research, disease surveillance (tracking cases and trends), prevention efforts, and treatment options for these conditions. Sickle cell disease disproportionately affects African Americans, while other heritable blood disorders impact various populations worldwide. The bill would primarily affect patients with these blood disorders, medical researchers, healthcare providers, and public health agencies like the CDC and NIH.

Key provisions would probably include funding for scientific research into better treatments and cures, improved tracking systems to understand disease prevalence, public health initiatives for prevention and early detection, and support for patient care. The specific funding amounts and detailed program requirements would be determined during the committee review process. **Current Status:** The bill is currently in committee, meaning it has been introduced but not yet debated or voted on by the full House. The bill was sponsored by Representative John James (R-MI) and would need to pass committee, then receive a full House vote before moving to the Senate.